Gastroenterology Research and Practice / 2015 / Article / Tab 4

Review Article

Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer

Table 4

Phase III clinical trials of FGFR-targeting agents.

Agent TargetType of cancerPhaseCombined regimen (comparative arm)Status or resultReference

Cediranib (AZD2171)FGFR and VEGFRCRCIIIFOLFOX or CAPOX (FOLFOX or CAPOX + placebo)Negative on OS[59]
CRCIIIFOLFOX (FOLFOX + bevacizumab)Negative on PFS[60]
NSLSCIIICarboplatin + paclitaxel (carboplatin + paclitaxel + placebo)Negative on PFS/OS[61]

Brivanib (BMS582664)FGFR and VEGFRCRC (wild-type KRAS)IIICetuximab (cetuximab + placebo)Negative on OS[62]
HCCIIINone (sorafenib)Negative on OS[63]
HCCIIINone (placebo)Negative on OS[64]

Dovitinib (TKI258)FGFR, VEGFR, PDGFR, FLT-3, KIT, and CSF-1RCCIIINone (sorafenib)Negative on PFS[65]

Nintedanib (BIBF1120)FGFR, VEGFR, PDGFR, FLT-3, and LCKNSCLCIIIDocetaxel (docetaxel + placebo)Positive on PFS [66]

Lenvatinib (E7080) FGFR, VEGFR, and PDGFRHCCIIINone (sorafenib)Ongoing[68]
ThyroidIIINone (placebo)Ongoing[69]

Orantinib (TSU68)FGFR, VEGFR, and PDGFRHCCIIINone (placebo)Suspended[70]

CRC: colorectal cancer; NSCLC: non-small-cell lung cancer; HCC: hepatocellular carcinoma; RCC: renal cell carcinoma; FOLFOX: 5-fluorouracil + leucovorin + oxaliplatin; CAPOX: capecitabine + leucovorin + oxaliplatin; RFS: relapse-free survival; OS: overall survival.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.